HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Event-Driven

Chongqing Taiji Industry (Group) A / Event-Driven

Chongqing Taiji Industry (Group) A (600129 CH)

<ul>
<li>There are several ways for pharmaceutical companies to commercialize drugs. We analyzed the advantages and disadvantages and ranked them accordingly. Among them, out-licensing early-stage pipelines is the worst choice.</li>
<li>After 5-6 years of commercialization, China Biotech have reached the critical point of verifying the feasibility of business models. However, some companies are falling behind. We listed them below.</li>
<li>After the failure of China TCM’s privatization, CNPGC can choose to launch another privatization after 12 months. There’re also other methods to address the horizontal competition issue with Taiji Group.</li>
</ul>


There are several ways for pharmaceutical companies to commercialize drugs. We analyzed the advantages and disadvantages and ranked them accordingly. Among them, out-licensing early-stage pipelines is the worst choice.
After 5-6 years of commercialization, China Biotech have reached the critical point of verifying the feasibility of business models. However, some companies are falling behind. We listed them below.
After the failure of China TCM’s privatization, CNPGC can choose to launch another privatization after 12 months. There’re also other methods to address the horizontal competition issue with Taiji Group.


China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<ul>
<li>The real reason for CNPGC’s decision to abandon its promise may be "extraordinary". The "national security issue" seems to be a more reasonable explanation for the failure of this privatization.</li>
<li>A sustainable rebound in share prices will have to depend on obvious improvement in fundamentals and attractive dividends.We changed our valuation forecast. The investment logic of China TCM has changed.</li>
<li>China TCM may not deliver excess returns in the short term. If investors can't wait that long, offload directly and moving on to other opportunities is an option to consider.</li>
</ul>


The real reason for CNPGC’s decision to abandon its promise may be "extraordinary". The "national security issue" seems to be a more reasonable explanation for the failure of this privatization.
A sustainable rebound in share prices will have to depend on obvious improvement in fundamentals and attractive dividends.We changed our valuation forecast. The investment logic of China TCM has changed.
China TCM may not deliver excess returns in the short term. If investors can't wait that long, offload directly and moving on to other opportunities is an option to consider.


China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>The gross spreads of large HK merger arb situations have increased since 18 October. The widening spread is due to the unfortunate fallout from the China TCM deal break. </li>
<li>We assess the widening spreads of HK's merger arb situations on several factors. Deal risk of the HK merger arb situations is evaluated by allocating 15 points across each factor.</li>
<li>In descending order, the companies with the lowest deal risk are <a href="https://www.smartkarma.com/entities/haitong-securities-co-ltd-h" target="_blank" rel="noopener">Haitong Securities Co Ltd (H) (6837 HK)</a>, <a href="https://www.smartkarma.com/entities/cpmc-holdings-ltd" target="_blank" rel="noopener">CPMC Holdings (906 HK)</a>, <a href="https://www.smartkarma.com/entities/greatview-aseptic-packaging" target="_blank" rel="noopener">Greatview Aseptic Packaging (468 HK)</a>, <a href="https://www.smartkarma.com/entities/shanghai-henlius-biotech-inc" target="_blank" rel="noopener">Shanghai Henlius Biotech (2696 HK)</a>, and Canvest.</li>
</ul>


The gross spreads of large HK merger arb situations have increased since 18 October. The widening spread is due to the unfortunate fallout from the China TCM deal break. 
We assess the widening spreads of HK's merger arb situations on several factors. Deal risk of the HK merger arb situations is evaluated by allocating 15 points across each factor.
In descending order, the companies with the lowest deal risk are Haitong Securities Co Ltd (H) (6837 HK), CPMC Holdings (906 HK), Greatview Aseptic Packaging (468 HK), Shanghai Henlius Biotech (2696 HK), and Canvest.


HK Merger Arb: Evaluating the Post China TCM Widening Spreads

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Malaysia Airports Holdings / Event-Driven

<ul>
<li>On the 30th October, Malaysian Aviation Commission (Mavcom) said Gateway Development Alliance (GDA)'s proposed privatisation of <a href="https://www.smartkarma.com/entities/malaysia-airports-holdings-bhd" target="_blank" data-smartkarma-citation="entities:117:1" rel="noopener">Malaysia Airports  (MAHB MK)</a> did not infringe on the Malaysian Aviation Commission Act 2015.</li>
<li>Mavcom followed that statement with it “welcomes any party to submit written feedback on the proposed decision by email .. by ..  Nov 6”. So, it's been approved or not?</li>
<li>In addition, there was conjecture earlier this year whether Mavcom, which will shortly be subsumed by the Civil Aviation Authority of Malaysia, had the clout to prevent the MAHB deal.  </li>
</ul>


On the 30th October, Malaysian Aviation Commission (Mavcom) said Gateway Development Alliance (GDA)'s proposed privatisation of Malaysia Airports  (MAHB MK) did not infringe on the Malaysian Aviation Commission Act 2015.
Mavcom followed that statement with it “welcomes any party to submit written feedback on the proposed decision by email .. by ..  Nov 6”. So, it's been approved or not?
In addition, there was conjecture earlier this year whether Mavcom, which will shortly be subsumed by the Civil Aviation Authority of Malaysia, had the clout to prevent the MAHB deal.  


Malaysia Airports (MAHB MK): Mavcom Approval. Sort Of

<ul>
<li>We summarise the latest spreads and newsflow of merger arb situations we cover across Hong Kong, Australia, New Zealand, Singapore, Japan, Indonesia, Malaysia, Philippines, Thailand and Chinese ADRs.</li>
<li>Highest spreads: <a href="https://www.smartkarma.com/entities/seven-i-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:1041:1" rel="noopener">Seven &amp; I Holdings (3382 JP)</a>, <a href="https://www.smartkarma.com/entities/beijing-capital-grand-ltd" target="_blank" data-smartkarma-citation="entities:18241:1" rel="noopener">Beijing Capital Grand (1329 HK)</a>, <a href="https://www.smartkarma.com/entities/shanghai-henlius-biotech-inc" target="_blank" data-smartkarma-citation="entities:27888:1" rel="noopener">Shanghai Henlius Biotech (2696 HK)</a>, <a href="https://www.smartkarma.com/entities/canvest-environmental-protection-group-co-ltd" target="_blank" data-smartkarma-citation="entities:100:1" rel="noopener">Canvest Environmental Protection Group (1381 HK)</a>, <a href="https://www.smartkarma.com/entities/greatview-aseptic-packaging" target="_blank" data-smartkarma-citation="entities:10802:1" rel="noopener">Greatview Aseptic Packaging (468 HK)</a>. 
</li>
<li>Lowest spreads: <a href="https://www.smartkarma.com/entities/platinum-asset-management" target="_blank" data-smartkarma-citation="entities:914:1" rel="noopener">Platinum Asset Management (PTM AU)</a>, <a href="https://www.smartkarma.com/entities/silverlake-axis-ltd" target="_blank" data-smartkarma-citation="entities:14150:1" rel="noopener">Silverlake Axis (SILV SP)</a>, <a href="https://www.smartkarma.com/entities/nec-networks-system-integr" target="_blank" data-smartkarma-citation="entities:16396:1" rel="noopener">Nec Networks &amp; System Integr (1973 JP)</a>, <a href="https://www.smartkarma.com/entities/t-gaia-corp" target="_blank" data-smartkarma-citation="entities:8339:1" rel="noopener">T Gaia Corp (3738 JP)</a>, <a href="https://www.smartkarma.com/entities/elematec-corp" target="_blank" data-smartkarma-citation="entities:2866:1" rel="noopener">Elematec Corp (2715 JP)</a>. </li>
</ul>


We summarise the latest spreads and newsflow of merger arb situations we cover across Hong Kong, Australia, New Zealand, Singapore, Japan, Indonesia, Malaysia, Philippines, Thailand and Chinese ADRs.
Highest spreads: Seven &amp; I Holdings (3382 JP), Beijing Capital Grand (1329 HK), Shanghai Henlius Biotech (2696 HK), Canvest Environmental Protection Group (1381 HK), Greatview Aseptic Packaging (468 HK). 

Lowest spreads: Platinum Asset Management (PTM AU), Silverlake Axis (SILV SP), Nec Networks &amp; System Integr (1973 JP), T Gaia Corp (3738 JP), Elematec Corp (2715 JP). 


Merger Arb Mondays (04 Nov) - Haitong, Canvest, Capital Grand, Capitol, Fuji Soft, NESIC, Elematec

Hong Kong

China Traditional Chinese Medicine Holdings Co. Ltd. is an investment holding company engaged in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products. It offers concentrated TCM granules, healthcare products, decoction pieces, and finished drugs, as well as Chinese medical healthcare solutions. The company was founded in 1905 and is headquartered in Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

China Traditional Chinese Medicine (570 HK)

China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji

Out-licensing early-stage pipelines is the worst option. China Biotech at a critical point in verifying business models. CNPGC has other methods to...

Xinyao (Criss) Wang

China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook

China TCM's decision to abandon privatization may be due to national security concerns. We lowered 2024 forecast. Valuation rebound rely on...

Xinyao (Criss) Wang

HK Merger Arb: Evaluating the Post China TCM Widening Spreads

The gross spreads of large HK merger arb situations have increased since 18 October, the China TCM deal break date. We assess the spreads of HK's...

Arun George

Malaysia Airports (MAHB MK): Mavcom Approval. Sort Of

The gross spread, is the tightest since the deal was first announced. Malaysian politics aare tricky. Tough situation to recommend. Even tougher...

David Blennerhassett

Merger Arb Mondays (04 Nov) - Haitong, Canvest, Capital Grand, Capitol, Fuji Soft, NESIC, Elematec

This week, the highest gross spreads are Seven & I (28.8%), Capital Grand (18.1%), Henlius (13.1%), Canvest (12.4%), GA Pack (10.0%), Shinko...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji

Out-licensing early-stage pipelines is the worst option. China Biotech at a critical point in verifying business models. CNPGC has other methods to...

Xinyao (Criss) Wang

China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook

​China TCM's decision to abandon privatization may be due to national security concerns. We lowered 2024 forecast. Valuation rebound rely on...

Xinyao (Criss) Wang

HK Merger Arb: Evaluating the Post China TCM Widening Spreads

The gross spreads of large HK merger arb situations have increased since 18 October, the China TCM deal break date. We assess the spreads of HK's...

Arun George

Malaysia Airports (MAHB MK): Mavcom Approval. Sort Of

The gross spread, is the tightest since the deal was first announced. Malaysian politics aare tricky. Tough situation to recommend. Even tougher...

David Blennerhassett

Merger Arb Mondays (04 Nov) - Haitong, Canvest, Capital Grand, Capitol, Fuji Soft, NESIC, Elematec

This week, the highest gross spreads are Seven & I (28.8%), Capital Grand (18.1%), Henlius (13.1%), Canvest (12.4%), GA Pack (10.0%), Shinko...

Arun George

China TCM's decision to abandon privatization may be due to national security concerns. We lowered 2024 forecast. Valuation rebound rely on...